Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 06, 2023, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg".
Press Release Jan 06 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Earlier from Alembic Pharmaceuticals
- Press Release Dec 26 2022
- Press Release Dec 22 2022
- Press Release Dec 09 2022
- Press Release Dec 01 2022
- Press Release Nov 21 2022
Later from Alembic Pharmaceuticals
- Press Release Jan 19 2023
- Press Release Mar 01 2023
- Alembic Pharmaceuticals Limited Press Release Mar 06 2023
- Alembic Pharmaceuticals Limited Press Release Mar 08 2023
- Press Release Mar 09 2023
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals